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Background: Inhaled endotoxin induces airways’neutrophilia, in human. TNF-a being a key cytokine in the response
to endotoxin, the effect of anti-TNF on the endotoxin-induced neutrophilic response was evaluated among healthy
volunteers.
Methods: Among a population of 30 healthy subjects, an induced-sputum was collected 2 weeks before, and
24 hours after an inhalation of 20 mcg endotoxin (E coli 026:B6). Then, the subjects were randomized into 3 parallel
groups treated with control, oral methylprednisolone 20 mg/day during 7 days or anti-TNF (adalimumab, Humira®,
Abbott) 40 mg SC. One week later, an induced-sputum was sampled, 24 hours after an inhalation of endotoxin.
Results: After endotoxin inhalation, the number of total cells, neutrophils and macrophages was significantly
increased (p <0.001). Compared to the response to endotoxin among the control group, anti-TNF inhibited the
endotoxin-induced neutrophil influx, both in relative (51.3 (±6.4)% versus 26.2 (±5.3)%, p <0.002) and in absolute
values (1321 (443–3935) cells/mcL versus 247 (68–906) cells/mcL, p <0.02). The endotoxin-induced neutrophilic
response was not significantly modified among the control group and oral corticosteroid group.
Conclusions: While oral corticosteroid had no effect, anti-TNF inhibited the neutrophil influx in sputum, induced by
inhalation of endotoxin, in human subject. The endotoxin model could be an early predictor of clinical efficacy of
novel therapeutics.
Trial registration: ClinicalTrials.gov NCT02252809 (EudraCT2008-005526-37)
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Over one bilion people through the World suffer from
chronic respiratory diseases (CRD), mainly chronic ob-
structive pulmonary diseases (COPD) and asthma [1].
Currently there is no satisfactory treatment for COPD
and severe asthma. Airways’ neutrophilic inflammation
is a risk factor of severity of several CRD. The number
of neutrophils in sputum correlates with the severity [2]
and accelerated decrease of FEV1 [3] in COPD and with
severe exacerbations in asthma [4]. Neither oral cortico-
steroids (CS), nor a high dose inhaled CS has an effect
on the airways’ neutrophilic inflammation in COPD* Correspondence: omichel@ulb.ac.be
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unless otherwise stated.[5,6], and neutrophilic exacerbations of asthma are re-
fractory to increasing the dose of inhaled corticosteroids
[7]. Through the activation of NF-kB, TNF-a induces the
IL-8 chemokine that is a chemoattractant for the neutro-
phils. Consistently, some studies reported that the con-
centrations of TNF-a and its soluble receptor are raised
in the sputum of COPD patients [8]. The lack of anti-
inflammatory effects of CS in COPD could be related to
the reduction in recruitment of histone desacetylase-2
by CS, resulting in the absence of control of NFkB tran-
scription, leading to expression of cytokines such as
TNF-a and IL-8 [9]. Thus, TNF-a appears to participate
to the mechanism of airways neutrophilic inflammation
in COPD and severe asthma.
The endotoxin-induced airways’ inflammation mimicks
several aspects of acute exacerbation of COPD [10]. ThisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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olone [11]. In an ex-vivo model, using endotoxin exposure
of lung tissue from COPD, TNF was the initial cytokine
and was predicitive for the following release of IL-6,
CXCL8 and IL-10. It was inhibited by the neutralisation of
the TNFα [12]. The concentration of TNF in the broncho-
alveolar lavage was significantly increased during the early
phase [2 hours] after bronchial endotoxin instillation in hu-
man [13]. Recently the involvement of NF-kB activation in
the neutrophilic response to inhaled endotoxin has been
reported among smokers [14].
Since TNF-a seems to be a key cytokine in endotoxin-
induced neutrophilic inflammation, the current study
evaluated the inhibiting effect of anti-TNF on the neu-




A population of 49 healthy, male and female, non-smoker
volunteers (age 18 to 50 years) was screened, after a writ-
ten informed consent was obtained from each subject.
They were excluded if they used drugs within 2 weeks or
over-the counter medication.
Study design
During the screening phase, an induced-sputum was col-
lected 2 weeks before, and 24 hours after an inhalation of
20 mcg endotoxin. On day 1, among the 49 healthy volun-
teers, 40 were selected after having produced a valid spu-
tum (defined as a 80% or more viability, with less than
50% squamous cells, and less than 70% neutrophils). A
significant inflammatory response to inhaled endotoxin
was defined as an increase of 10% or more of the absolute
count of neutrophils in the sputum. By doing so, 30 sub-
jects were included (mean age: 31.0 (28 – 34) years; fe-
males/males: 16/14) (Figure 1).
After a wash-out period of 7 days, they were randomised
into 3 open parallel groups: control or treated with 20 mg
oral prednisolone (Medrol®, Pfizer-Upjohn) once daily forFigure 1 The design of the study.7 days (PDN) or a single sub-cutaneous anti-TNF antibody,
40 mg adalimumab (Humira®, Abbott) on day 1. On day 14,
a challenge test with inhaled endotoxin was performed in
each subject and an induced-sputum was obtained 24 hours
later. A clinical follow-up visit was performed after 5 weeks.
Induced sputum
Hypertonic sterile saline (5%) was nebulized for 30 minutes
with an ultrasonic nebulizer (Fisoneb; Karapharm,
Marseille, France); subjects rinsed their mouth with water
every 10 minutes and tried to cough sputum directly into
a sterile plastic box. After selection of all portions of spu-
tum as free as possible of saliva, the plugs were weighed,
mixed with 4 volumes of dithiotreitol 0.1% (Sputolysin;
Behring Diagnostics, Somerville, NJ), homogenised and
rocked for 15 min. before adding 4 volumes of Dulbecco’s
PBS. After filtration and centrifugation (15 minutes at
800 g) the supernatant was frozen at -80°C while the pel-
leted cells were resuspended in PBS. The number of total
cells was measured with a Thoma's hemocytometer. The
cell viability was assessed by the Trypan blue method. A
slide was prepared by centrifugation (Cytospin, Shandon
Inc, Pittsburgh, PA) and stained with May-Grünwald-
Giemsa. The differential cells were counted on 400 cells.
Endotoxin challenge tests
The procedure of endotoxin challenge has been previ-
ously reported [15]: briefly 20 μg of a suspension of lipo-
polysaccharide (LPS Escherichia coli 026:B6 from Sigma
Chemical, St Louis, MO -ref L-2654), the active deriva-
tive of endotoxin, was administered by a dosimeter
Mefar MB3 (Mefar, Brescia, Italy). The dose of inhaled
endotoxin corresponded to 17 inhalations of a calibrated
aerosol of 6 mcL/inhalation containing a solution of
0.2 mg/mL endotoxin. Outputs was checked by weighing
the nebulizer containing 2 ml of sterile normal saline be-
fore and after 10 actuations [16]. The endotoxin dose
was selected according to data published on the dose–
response relationship to inhaled endotoxin [17]. The ob-
jective was to cause only minimal systemic responses,
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responses in the lung, to allow prednisolone and/or adali-
mumab to significantly reduce these responses. At the end
of the procedure, the volunteers were instructed to rinse
their mouth to eliminate residual endotoxin trapped on
the oral mucosa. Symptoms, oral temperature, forced vital
capacity (FVC), forced expiratory volume in 1 second
(FEV1) and the FEV1/FVC were recorded before and
hourly after endotoxin.Good clinical practice
This study was conducted according to with Good Clinical
Practice Guidelines of the International Conference on
Harmonisation. The study was registered in the non-public
database of all drugs trials in the European Community
(EudraCT: 2008-005526-37), as an exploratory phase study,
in 2008, and then in the public database form the Clinical-
Trials.gov NCT02252809. It was approved by the Ethics
Committee of the CHU Brugmann (decision number
CE2008/49) and the competent authorities in Belgium.
Written informed consent was obtained in each subject.
The Clinical Research Unit of the Institution was respon-
sible for study coordination.Statistics
The results were expressed as mean or geometric
mean ±95% confidence interval. The absolute values
of the cells were Log transformed. Repeatability of
the response to LPS was assessed, among the control
group, by plotting the differences between repeated
measurements against the mean of the repeated
measures, and testing whether the mean differences
was significantly different from 0 (method of Bland
and Altman) [18]. ANOVA was used to compare
change from baseline among the three groups (con-
trol, PDN, anti-TNF), followed by paired t-tests be-
tween each active treatments and the control group.
P values smaller than 0.05 were considered statisti-





Age (years, 95% CI)† 31 (28–34)
Weight of sputum plugs (mg, 95% CI)‡ 469 (389–553)
Cells viability (%, 95% CI)† 80.4 (76.0-84.7)
Total cells (cells/μL, 95% CI)‡ 2280 (1496–3467)
†arithmetic means; ‡geometric means.
*age, sputum characteristics were not significantly different among female (F) compResults
The demographics of the population is shown in Table 1.
There was no significant difference among the 3 rando-
mised groups for age, sex ratio, sputum characterictics
at the basal state.
Except a slight headache among 5 subjects, there was
no significant symptom or change in lung function. The
temperature increased slighly from 36.3 (36.0-36.6) im-
mediately before LPS to 36.3 (36.0-36.5) (p = NS), 36.3
(36.2-36.7) (p = NS), 36.4 (36.1-36.6) (p = NS) , 36.5
(26.2-36.8) (p <0.05), at 2, 4, 8 and 24 hours after inhaled
LPS, respectively. There was no significant drug effect
on the symptoms and/or the temperature.
Among the 30 subjects, during the screening phase, the
endotoxin inhalation induced a significant rise of the geo-
metric means of total viable cells (p <0.0001), neutrophils
(p <0.0001), macrophages (p <0.001), and lymphocytes
(p <0.0001) (Figure 2A). The arithmetic means of the per-
centage of neutrophils increased from 35.0 (26.9 – 43.1)%
to 52.4 (44.6 – 60.3)%, (p <0.0001), while there was a de-
crease of macrophages from 60.7 (52.2 – 62.2)% to 43.8
(35.9 – 51.8)%, (p <0.0001) (Figure 2A). Among the sub-
jects of the control group, the neutrophilic (%) response
correlated significantly between the 2 endotoxin chal-
lenges (i.e. the endotoxin challenge before and after ran-
domisation, r = 0.78; p <0.02), suggesting that the
response was reproducible. The intra-subject repeatability
of the method was evaluated in the control group, by
comparing the neutrophilic response on day 1 and day 14
(Figure 2B). The Bland and Altman analysis showed that
the measurements of percentage and absolute values of
neutrophils were not statistically different between day 1
and day 14 (t-test = −0.179 and −0.585, respectively).
Anti-TNF inhibited the neutrophil influx both in relative
(51.3 (36.8 - 65.8)% versus 26.2 (14.1 – 38.2)% , p <0.002),
and in absolute value (1321 (443–3935) cells/mcL versus
247 (68–906) cells/mcL, p <0.02) (Figure 3). While anti-
TNF increased the percentage of macrophages (44.7(29.8 –
59.6)% versus 71.3 (58.4 – 84.1)% ; p <0.002), it had no sig-
nificant effect on the absolute count of macrophages (1180




29 (23–34) 33 (27–40) 31 (25–37)
564 (378–750) 422 (309–535) 433 (260–606)
80.7 (73.7-87.6) 85.6 (78.3-92.8) 74.8 (65.5-84.2)
4083 (1749–9506) 2138 (933–4909) 1356 (764–2404)
ared to male (M).
Figure 2 The change of the sputum cells count after LPS inhalation compared to saline inhalation. A. Sputum cells count before and
24 hours after inhalation of 20 mcg endotoxin during the screening phase, among the 30 included subjects. The black bar indicates the cells counts
after saline, the white bar after endotoxin inhalation. Data (in % or log absolute value) are expressed as means +95% CI. Statistics: paired t-tests
(n = 30). B. Assesment of repeatability of the LPS induced neutrophils (% and absolute values). The differences against the means of the neutrophils
counts, after repeated inhaled LPS at day 1 and day 14, among the control group. Limits of agreement are the mean ±2 SD.
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effect on the neutrophils and macrophages response to
endotoxin, while it inhibited significantly the percentage
but not the absolute count of lymphocytes (Figure 3). The
data of the endotoxin-induced cells count response in spu-
tum before and after a treatment are shown in Table 2.
The endotoxin-induced changes of the cell counts of
the control group were compared to the changes aftertreatment with corticosteroids or anti-TNF (Figure 4,
ANOVA for repeated measurements). The F-tests were
significant for PMN % (F226 = 8.07, p <0.01), macrophages
% (F227 = 8.27, p <0.01), viability % (F
2
26 = 5.69, p <0.01),
and Log PMN (F226 = 4.33 , p <0.03), but not for Log mac-
rophages, Log lymphocytes and lymphocytes %.
The amplitude of the neutrophil response to endo-
toxin, expressed in absolute values was variable among
Figure 3 Comparisons of LPS-induced cell counts before and after treatment. The black bar indicates the cells counts after control, the
white bar after methylprednisolone and the gray bar after anti-TNF. Data are expressed as means +95% CI. Statistics: paired t-tests. *p <0.05,
**p <0.02, ***p <0.002.
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the basal state (Figure 5A). Anti-TNF totally inhibited
the endotoxin-induced rise of neutrophils, in each sub-
ject (exept one). The rise of the neutrophilic count after
endotoxin (Figure 5B) was significantly related to the
amplitude of the anti-TNF blocking effect, suggesting
that anti-TNF was mainly active on the endotoxin-
induced change in neutrophils but not, on the airways
neutrophils count at the basal state. There was no sig-
nificant change of the amplitude of the neutrophil re-
sponse to endotoxin in both the control groups and the
oral steroids treated subjects (Figure 5C and D).
Discussion
The study shown that a pretreatment with anti-TNF
inhibited the endotoxin-induced neutrophil influx in in-
duced sputum, among healthy subjects. Conversely, oral
corticosteroid had no effect on the endotoxin induced
inflammation.
In human, a bronchial instillation of endotoxin induced
an early phase reaction, occuring after 2 hours and charac-
terized by a local increase in neutrophils and cytokines,
such as TNF-a, IL1-b, IL-6 and IL-8 [13]; TNF-a increased
more than 300 fold, compared to the control [13]. It was
followed by a later phase (24–48 hours) characterized bythe presence of neutrophils, macrophages, macrophages
and lymphocytes [13,19], recovering within 7 days [19]. In
ex vivo lung tissue, stimulated with endotoxin (100 ng/
ml), TNF-a was the initial cytokine, expressed by the mac-
rophages and mastocytes as early as 1 hour, rising at 2 and
4 hours and peaking at 6 hours and it was also predictive
for the following release of cytokines, after endotoxin
exposure [12]. Since TNF-a is a key cytokine in endotoxin-
induced airway’ inflammation, we hypothesised that
anti-TNF could attenuate the endotoxin induced airways’
neutrophilia.
The current data confirmed the airways’ neutrophilic
response in absolute and relative value, 24 hours after an
inhalation of 20 mcg endotoxin. Firstly, we evaluated the
repeatability of the PMN response. It is well known that
the amplitude of the neutrophilic response to inhaled
endotoxin is highly variable between subjects [20], as
also confirmed by the present results. Nevertheless,in
the current study, among the 10 subjects submitted to
repeated endotoxin challenges, at 14 days interval, the
intra-subject repeatability of the sputum neutrophilia
was significant, consistently with recent data [14,21,22].
Secondly, we investigated the effect of oral corticoste-
roids on the endotoxin-induced airways’ neutrophilia. A
7 days pretreatment with methylprednisolone 20 mg daily
Table 2 The endotoxin-induced cells count response in sputum before and after a treatment with control, oralsteroids
and anti-TNF
Parameters Total Control PDN p value‡ Anti-TNF p value‡
.(1) .(2) (1) vs (2) .(3) (1) vs (3)
n 30 9 10 10
Total viable cells (cells/μL)
Before LPS 1811 (1191–2748) 2716 (1132–6741) 1820 (805–4111) 1000 (607–1648)
After LPS 4188 2754–6368) 4570 (2004–10399) 4447 (2060–9571) 2884 (1352–6152)
After LPS + treatment 6039 1883–19408) 3963 (2004–7834) NS 1261 (591–2691) 0.052
p value† < 0.0001
Neutrophils (cells/μL)
Before 520 (299)906) 789 (229–2710) 561 (207–1517) 244 (120–498)
After LPS 1954 (1135–3357) 1795 (560–5768) 2387 (1019–5598) 1321 (443–3935)
After LPS + treatment 2594 (614–10990) 2313 (1084–5284) NS 247 (68–906) < 0.02
p value† p <0.0001
Macrophages (cells/μL)
Before 993 (681–1449) 1438 (692–2985) 914 (395–2113) 656 (396–1089)
After LPS 1618 (1138–2296) 1786 (939–3396) 1644 (807–3350) 1180 (661–2089)
After LPS + treatment 1892 (647–5508) 1185 (528–2654) NS 873 (457–1660) NS
p value† p <0.001
Lymphocytes (cells/μL)
Before 39 (23–65) 65 (29–147) 33 (12–91) 21 (8–54)
After LPS 119 (71–201) 155 (64–378) 125 (54–299) 67 (20–219)
After LPS + treatment 198 (42–929) 54(18–156) NS 22 (3–159) NS
p value† p <0.0001
Neutrophils (%)
Before 35 .0 (26.9-43.1) 36.8 (18.3-55.3) 37.3 19.0-55.3) 28.2 (18.2-38.1)
After LPS 52.4 (44.6-60.3) 48.4 (27.1-69.8) 55.9 (44.0-67.8) 51.3 (36.8-65.8)
After LPS + treatment 49.6 (28.2-70.9) 63.8 (49.8-77.8) NS 26.2 (14.1-38.2) < 0.002
p value† p <0.0001
Macrophages (%)
Before 60.7 (52.2-62.2) 58.6 (39.8-77.5) 59.5 (39.5-79.5) 67.1 (57.2-77.0)
After LPS 43.8 (35.9-51.8) 47.8 (26.2-69.3) 40.8 (28.7-52.8) 44.7 (29.8-59.6)
After LPS + treatment 46.9 (24.5-69.3) 34.6 23.4-48.8) < 0.002 71.3 (58.4-84.1) NS
p value† p <0.0001
Lymphocytes (%)
Before 2.7 (1.5-3.9) 2.1 (0.8-3.4) 2.7 (0.6-4.8) 3.3 (0.1-6.3)
After LPS 3.0 (2.3-3.6) 3.1 (1.6-4.6) 3.1 (2.4-4.1) 2.8 (1.4-4.1)
After LPS + treatment 2.9 (0.9-5.0) 1.3 (0.6-2.0) NS 1.5 (0.3-3.2) 0.052
p value† NS
The % and absolute values are expressed as arithmetic or geometric means, respectively (95% Confidence Interval). PDN, methylprednisolone.
‡Unpaired t-tests were used to compare the changes among control (1) with the changes after prednisolone (2) or anti-TNF (3).
†Paired t-test to compare the cell counts before and after LPS, among the whole population.
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regiment did not have an effect on the response to 50 mcg
LPS, a dose that has been associated with clinical symp-
toms [11]. It was thought that exposure to a subclinical(and consequently sub-maximal) dose of LPS could be
blocked by oral steroids but it was not confirmed by
the current data. We can not excluded that for a lower
level of LPS exposure (such as 5 μg), an effect of oral
Figure 4 Comparison of the change of sputum cell counts after a treatment with control, prednisolone or anti-TNF. The red bar indicates
the change after treating with anti-TNF, the green bar is the change after methylprednisolone and the white bar is control. Data are expressed as
means +95% CI. ANOVA among the 3 treatments was applied followed by comparisons among the treatments; paired t-test applied when F-test
is significant. Statistics: paired t-tests. **p <0.02, ***p <0.002.
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significant; though at this level of exposure, the re-
sponse is inconsistent between subjects [14,17].
Thirdly, we have shown that, in contrast to corticoste-
roids, a pretreatment with anti-TNF blocked the neutro-
philic response, both in relative and absolute values. In
mirror with the decrease of the neutrophils, the percent-
age of macrophages increased, though the absolute num-
ber of macrophages remained unchanged after anti-TNF
treatment. Interestingly the current data shown that
anti-TNF had a blocking effect mainly on the rise of the
neutrophils rather than the basal sputum neutrophilia.
This suggests that anti-TNF could be active rather on
neutrophilic exacerbations, than on the basal state.
Patients with refractory asthma have evidence of up-
regulation of the TNF-α axis since they had increased
expression of membrane-bound TNF-α, TNF-α receptor
1, and TNF-α–converting enzyme by peripheral-blood
monocytes and a 10 weeks of treatment with the soluble
TNF receptor, etanercept, was associated with a signifi-
cant improve in non specific bronchial hyperresponsive-
ness, post bronchodilator FEV1 and asthma-related
quality of life [23]. In moderate asthma, the anti-TNF
infliximab had no effect on morning peak expiratory
flow, though it reduced of more than 50% the number of
moderate exacerbations [24]. A recent case series suggest-
ing that anti-TNF may improve the condition of severe
steroid-dependent refractory asthma, with frequent exacer-
bations and daily symptoms despite close repeated medical
evaluation and maximal treatment including oral steroids[25]. In animal model of allergen sensitization, on the con-
trary to corticosteroids, anti-TNF does not modify the al-
lergen ovalbumin-induced airways reaction. Though, when
ovalbumin is mixed with endotoxin, anti-TNF significantly
blocked the inflammatory reaction, suggesting that TNF
may play a more prominent pathogenic role in patients
with an environmental exposure to endotoxin [26].
The importance of TNF in severe corticoresistant asthma
was also suggested by increased protein and gene expres-
sion in the airways [27]. The gene expression profiling in
induced sputum, shown that upregulation of TNF was as-
sociated with neutrophilic asthma [28]. TNF-a is also be-
lieved to play a central role in the pathophysiology of
COPD [29]. Since, on one side severe asthma and COPD
are heterogeneous diseases with different phenotypes and
endotypes and, on the other side the TNF inhibitor have
blocking effect on endotoxin-induced airways’ neutrophilic
inflammation, future studies could investigate what kind of
patient can benefit from anti-TNF, in regard to their inflam-
matory sensitivity to endotoxin [30].
Other anti-inflammatory drugs have been evaluated
on endotoxin induced airways’ inflammation in hu-
man. Salmeterol was shown to have a significant anti-
inflammatory effect, even when a 100 μg dose of
inhaled endotoxin was used [31]. It has been reported
that neutrophilic inflammation induced by intra-nasal
instillation was reduced by inhibition of CXCR2
(a chemokine receptor antagonist) [32]. Recently an oral
CXCR2 antagonist inhibited the induced sputum inflam-
mation, induced by inhaled endotoxin, among healthy
Figure 5 The individual values of the PMN response after endotoxin. A. The individual values of Log count of neutrophils in sputum at the
basal state, after endotoxin inhalation(LPS) and after LPS with a previous treatment with anti-TNF (LPS + anti-TNF). B. The relationship between
the rise of the Log count of neutrophils in sputum after endotoxin (LPS) (vertical axis) with the inhibiting effect of anti-TNF on the LPS response
(horizontal axis). C. The individual values of Log count of neutrophils in sputum at the basal state, after endotoxin inhalation(LPS) and after LPS
among the control group. D. The individual values of Log count of neutrophils in sputum at the basal state, after endotoxin inhalation(LPS) and
after LPS with a previous treatment with oral steroids (PDN).
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sponses in vitro and in murine models of lung inflamma-
tion in vivo; a pretreatment with simvastatinreduced the
lung neutrophilic response induced by LPS inhalation in
human volunteers [34]. The PDE-4 inhibitors have been
also evaluated on the LPS model. Roflumilast reduced the
neutrophilic into the airways after segmental bronchial
challenge with endotoxin [35] – however not confirmed in
a recent study using GMP-grade LPS [21] -, while cilomi-
last had no effet on the endotoxin-induced sputum neu-
trophila [11]. Interestingly, the phase III development of
cilomilast have been stopped due to a lack of efficacy,
while roflumilast has received post-phase III market auto-
risation. Recently it has been reported that in human vol-
unteers, a pretreatment with vitamin E decreased the
neutrophilic airways’ response induced by endotoxin [36].
The data obtained with the endotoxin model among
healthy subjects have been extrapolated to the COPD pa-
tients. Based on their own data, R Kitz et al. concludedthat the endotoxin inflammation is a model to investigate
the inflammatory response in human and to improve our
understanding of the mechanism of chronic respiratory
diseases [37]. Because inhalation of endotoxin induced in-
flammation mimicking several characteristics of COPD,
Korsgen et al. considered that the endotoxin model in hu-
man could be used for initial human studies of novel
COPD-drugs [38]. According to Aul et al., the endotoxin
response could be a suitable model of bacterial exacerba-
tions of COPD since the response is safe, reproducible
and associated to translocation of the NF-kB subunit p65
in sputum cells [14]. In a brief review comparing the
endotoxin model with ozone and rhinovirus challenges,
the endotoxin is the model of choice for new drugs involv-
ing the TLR4 receptor, and NF-kB pathway [39]. Since the
current data show that endotoxin inflammation is inhib-
ited by adalimumab, a TNF inhibitor, this last could be
used as a positive control, in future studies evaluating
novel agents.
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While oral corticosteroid was not effective, the TNF in-
hibitor adalimumab blocks the endotoxin-induced neu-
trophilic airways’ inflammation.
Firstly, this endotoxin model could be used to under-
stand the biological effects of compounds that inhibit the
LPS induced NF-kB pathway and/or be a model of acute
exacerbation of COPD and it could be an early predictor
of clinical efficacy of novel therapeutics. Secondly, an anti-
TNF treatment could be indicated in chronic respiratory
diseases with acute neutrophilic airways’ exacerbations, in
particular related to endotoxin sensitivity and/or environ-
mental exposure.
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